Probiont is developing personalized solutions for cancer immunotherapy efficacy testing. Our technology is purposed to enable rapid screening of cancer drugs used in immunotherapy, for early identification of effective treatment strategies for individual patients.
-
- Founding year:
2021
-
- Development phase:
Prototype
-
- Funding stage:
Pre-seed
-
- Website:
-
- Contact person info:
benedek.poor(at)probiont.fi
-
- Team members:
3
Recent Comments